Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AxoGen Inc    AXGN

AXOGEN INC (AXGN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
16.03 USD   +4.36%
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against AxoGen, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 07:31pm EST

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on behalf of those who acquired AxoGen, Inc. (“AxoGen” or the “Company”) (NASDAQ: AXGN) securities during the period from August 7, 2017 through December 18, 2018 (the “Class Period”). Investors have until March 11, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that AxoGen failed to disclose that: (i) the Company aggressively increased prices to mask lower sales; (ii) the Company’s pricing alienated customers and threatened the Company’s future growth; (iii) the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (iv) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (v) the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; and (vi) the Company’s key operating metrics, such as number of active accounts, were overstated.

Following the publication of a report by Seligman Investments alleging channel stuffing and the overstatement of active accounts, the price of AxoGen shares fell by $6.17, or approximately 22.4%, to close at $21.36 on December 18, 2018.

If you acquired AxoGen securities during the Class Period, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AXOGEN INC
01/18AXOGEN, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
01/17SCOTT+SCOTT ATTORNEYS AT LAW LLP : Alerts Investors to Securities Class Action A..
BU
01/17KESSLER TOPAZ MELTZER & CHECK, LLP : Announces Investor Securities Fraud Class A..
BU
01/17AXOGEN : Announces RECON Study Update
AQ
01/16AXOGEN, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
01/16AXOGEN : Announces RECON Study Update
AQ
01/15DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
01/15ROBBINS ARROYO LLP : AxoGen, Inc. (AXGN) Misled Shareholders According to Class ..
BU
01/15AxoGen Announces RECON® Study Update
GL
01/14GLANCY PRONGAY & MURRAY LLP : Reminds Investors of the Deadline in the Class Act..
BU
More news
Financials ($)
Sales 2018 84,4 M
EBIT 2018 -15,9 M
Net income 2018 -21,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 7,34x
Capi. / Sales 2019 5,45x
Capitalization 620 M
Chart AXOGEN INC
Duration : Period :
AxoGen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXOGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 36,0 $
Spread / Average Target 125%
EPS Revisions
Managers
NameTitle
Karen L. Zaderej Chairman, President & Chief Executive Officer
Mike Donovan Vice President-Operations
Peter J. Mariani Chief Financial Officer
Ivica Ducic Medical Director-Clinical & Translational Sciences
Angelo G. Scopelianos Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
AXOGEN INC-21.54%620
THERMO FISHER SCIENTIFIC7.54%96 884
DANAHER CORPORATION4.20%73 994
INTUITIVE SURGICAL13.29%61 959
BOSTON SCIENTIFIC CORPORATION6.65%52 155
ILLUMINA4.27%45 974